Sickle cell anemia and vascular dysfunction: The nitric oxide connection

Journal of Cellular Physiology

Volumn 224, Issue 3, 2010, Pages 620-625

  Akinsheye, Idowu ^a   Klings, Elizabeth S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACTIVIN RECEPTOR LIKE KINASE 1; ALLOPURINOL; ARGININE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEME OXYGENASE 1; HEMOGLOBIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LACTATE DEHYDROGENASE; N(G) METHYLARGININE; NARCOTIC AGENT; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SILDENAFIL; SODIUM NITRATE; VASCULAR CELL ADHESION MOLECULE 1; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; CELL PROTECTION; CLINICAL TRIAL; CYTOTOXICITY; ENDOTHELIAL DYSFUNCTION; GENETIC PREDISPOSITION; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; THROMBOCYTOPOIESIS; VASCULAR DISEASE;

ANEMIA, SICKLE CELL; ANIMALS; ENDOTHELIUM, VASCULAR; GENETIC PREDISPOSITION TO DISEASE; HEMOGLOBINS; HEMOLYSIS; HUMANS; HYPERTENSION, PULMONARY; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDANTS; OXIDATIVE STRESS; XANTHINE OXIDASE;

EID: 77954599927     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22195     Document Type: Review

References (68)

1. Alderton WK, Cooper CE, Knowles RG. 2001. Nitric oxide synthase: Structure, function, and inhibition. Biochem J 357: 593-615.
2. Alonso D, Radomski M. 2003. Nitric oxide, platelet formation, myocardial infarction and reperfusion therapies. Heart Fail Rev 8:47-54. (Pubitemid 36355813)
3. Alvarez B, Radi R. 2003. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 25:295-311. (Pubitemid 38041267)
4. Ashley-Koch A, Elliot L, Kail ME, De Castro LM, Jonassaint J, Jackson TL, Price J, Ataga KI, Levesque MC, Weinberg JB, Orringer EP, Collins A, Vance JM, Telen MJ. 2008. Identification of genetic polymorphisms associatedwith risk for pulmonary hypertension in sickle cell disease. Blood 111:5721-5726.
5. Aslan M, Freeman BA. 2007. Redox-dependent impairment of vascular function in sickle cell disease. Free Radic Biol Med 43:1469-1483. (Pubitemid 47615401)
6. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I, White CR, Freeman BA. 2001. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 98:15215-15220.
7. Aslan M, Thornley-Brown D, Freeman BA. 2006. Reactive species in sickle cell disease. Ann NY Acad Sci 899:375-391.
8. Barnett CF, Hsue PY, Machado RF. 2008. Pulmonary hypertension: An increasingly recognized complication of hereditary hemolytic anemias and HIV infection. JAMA 299:324-331.
9. Beckman JS, Crow JP. 1993. Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans 21:330-334.
10. Belcher JD, Mahaseth H, Welch ET, Otterbein EL, Hebbel PR, Vercellotti, G.M. 2006. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 116:808-816. (Pubitemid 43326890)
11. Benisty JI. 2002. Cardiology patient page. Pulmonary hypertension. Circulation 106:e192-e194.
12. Bowers R, Cool C, Murphy RC, Tuder RM. 2004. Oxidants are produced in the lungs of patients with pulmonary hypertension as a result of ischemia or tissue hypoxia. Am J Resp Crit Care Med 169:764-769.
13. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD. 2006. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: A HuGE review. Am J Epidemiol 164:921-935. (Pubitemid 44729832)
14. Chan AC, Chow CK, Chiu D. 1999. Interaction of antioxidants and their implication in genetic anemia. Proc Soc Exp Biol Med 222:274-282.
15. Dasgupta T, Hebbel RP, Kaul DK. 2006. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med 41:1771-1780.
16. Davies KJ, Pryor WA. 2005. The evolution of free radical biology & medicine: A 20-year history. Free Radic Biol Med 39:1263-1264.
17. De Castro LM, Jonassaint FL, Graham F, Ashley-Koch A. 2008. Pulmonary hypertension associatedwith sickle cell disease: Clinical and laboratory endpoints and disease outcomes. Am J Hematol 83:19-25.
18. de Franceschi L, Baron A, Scarpa A, Adrie C, Janin A, Barbi S, Kister J, Rouyer-Fessard P, Corrocher R, Leboulch P, Beuzard Y. 2003. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood 102:1087-1096.
19. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC Hauser DL Criner GJ Davis K Jr., Hyers TM, Papadakos P. 1998. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 26:15-23.
20. Durante W, Kroll MH, Christodoulides N, Peyton KJ, Shafer AI. 1997. Nitric oxide induces heme oxygenase-1 gene expression and carbon mono-oxide production in vascular smooth muscle cells. Circ Res 80:557-564. (Pubitemid 27137293)
21. Eberhardt R, McMahon L, Duffy S, Steinberg MH. 2003. Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol 74:104-111. (Pubitemid 37187726)
22. Fox-Robichaud A, Payne D, Hasan S, Ostrovsky L. 1998. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest 101:2497-2505. (Pubitemid 28270444)
23. Frenette PS, Atweh GF. 2007. Sickle cell disease: Old discoveries, new concepts, and future promise. J Clin Invest 117:850-858.
24. Gladwin MT, Vichinsky E. 2008. Pulmonary complications of sickle cell disease. N Engl J Med 359:2254-2265.
25. Gladwin MT, Schechter AN, Ognibene FP, Coles WA, Reiter CD, Schenke WH, Csako G, Waclawiw MA, Panza JA, Cannon RO. 2003. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 107:271-278. (Pubitemid 36135223)
26. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minster K, Brown B, Coles WA, Nichols, JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. 2004. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350:886-895.
27. Gladwin MT, Schechter AN, Kim-Shapiro, D.B., Patel RP, Hogg N, Shiva S, Cannon RO, Kelm M, Wink DA, Espey MG, Oldfield EH, Pluta RM, Freeman BA, Lancaster JR, Feelisch M Lundberg JO. 2005. The emerging biology of the nitrite anion. Nat Chem Biol 1:308-314.
28. Hsu LL, Champion HC, Campbell-Lee S.A., Bivalacqua T.J., Manci EA, Diwan BA, Schimel DM, Cochard A, Wang X, Schechter AN, Noguchi CT, Gladwin MT. 2007. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 109:3088-3098.
29. Irvine JC, Ritchie RH, Favaloro JL, Andrews KL, Widdop RE, Kemp- Harper BK. 2008. Nitroxyl (HNO): The Cinderella of the nitric oxide story. Trends Pharmacol Sci 29:601-608.
30. Kato GJ, Onyekwere OC, Gladwin MT. 2007. Pulmonary hypertension in sickle cell disease: Relevance to children. Pediatr Hematol Oncol 24:159-170. (Pubitemid 46650754)
31. Kaul DK, Liu XD, Fabry ME, Nagel RL. 2000. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol 278:H1799-H1806.
32. Kaul DK, Zhang X, Dasgupta T, Fabry ME. 2008. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. Am J Physiol Heart Circ Physiol 295:H39-H47.
33. Kelley EE, Wagner BA, Buettner GR, Burns CP. 1999. Nitric oxide inhibits iron-induced lipid peroxidation in HL-60 cells. Arch Biochem Biophys 370:97-104. (Pubitemid 29476955)
34. King SB. 2003. A role for nitric oxide in hydroxyurea-mediated fetal hemoglobin induction. J Clin Invest 111:171-172.
35. Lancaster JR, Jr. 2002. Reaping of nitric oxide by sickle cell disease. Proc Natl Acad Sci USA 99:552-553. (Pubitemid 34106547)
36. Loscalzo J, Welch G. 1995. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38:87-104.
37. Lundberg JO, Weitzberg E, Gladwin MT. 2008. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 7:156-167. (Pubitemid 351194063)
38. Machado RF, Martyr S, Kato GJ, Barst RJ, Anthi A, Robinson MR, Hunter L, Coles W, Nichols J, Hunter C, Sachdev V, Castro O, Gladwin MT. 2005. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 130:445-453. (Pubitemid 43899595)
39. Mack AK, McGowan V, Tremonti CK, Ackah D, Barnett CF, Machado R, Gladwin MT, Kato GJ. 2008. Sodium nitrite promotes regional blood flow in patientswith sickle cell disease: A phase I/II study. Br J Haematol 142:971-978.
40. Morris C. 2008. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology 177-185.
41. Morris C. 2009. Arginine Therapy for Vaso-Occlusive Pain Episodes in Sickle Cell Disease 51st ASH meeting. New Orleans.
42. Morris C, Morris SM, Jr., Hager W, van Warmerdam J, Claster S. 2003. Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 168:63-69.
43. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM, Jr., Gladwin MT. 2005. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294:81-90.
44. Morris CR, Suh JH, Hager W, Larkin S, Bland DA, Steinberg MH, Vichinsky EP, Shigenaga M, Ames B, Kuypers FA, Klings ES. 2008. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 111:402-410.
45. Nath KA, Shah V, Haggard JJ, Croatt AJ, Smith LA. 2000. Mechanism of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol 279:R1949-R1955.
46. Nath KA, Grande JP, Haggard JJ, Croatt A.J, Katusic ZS, Solovey A, Hebbel RP. 2001. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol 158:893-903.
47. Pritchard KA, Jr., Ou J, Ou Z, Shi Y, Franciosi JP, Signorino P, Kaul S, Ackland-Berglund C, Witte K, Holzhauer S, Mohandas N, Guice KS, Oldham KT, Hillery CA. 2004. Hypoxiainduced acute lung injury in murine models of sickle cell disease. Am J Physiol Lung Cell Mol Physiol 286:L705-L714.
48. Radi R. 1996. Reactions of nitric oxide with metalloproteins. Chem Res Toxicol 9:828-835.
49. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, Schechter AN, Gladwin MT. 2002. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8:1383-1389.
50. Rongen GA, Smits P, Thien T. 1994. Endothelium and the regulation of vascular tone with emphasis on the role of nitric oxide. Physiology, pathophysiology and clinical implications. Neth J Med 44:26-35.
51. Rother RP, Bell L, Hillmen P, Gladwin MT. 2005. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 293:1653-1662.
52. Ryter SW, Tyrrell RM. 2000. The heme synthesis and degradation pathways: Role in oxidant sensitivity: Heme oxygenase has both pro- and antioxidant properties. Free Radic Biol Med 28:289-309.
53. Searles CD. 2006. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression. Am J Physiol Cell Physiol 291:C803-C816.
54. Song Y, Jones JE, Beppu H, Keaney JF Jr., Loscalzo J, Zhang YY. 2005. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 112:553-562.
55. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. 1994. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 89:2035-2040.
56. Steinberg MH. 2008. Sickle cell anemia, the first molecular disease: Overview of molecular etiology, pathophysiology, and therapeutic approaches. Scientific World Journal 8:1295-1324.
57. Switzer CH, Flores-Santana W, Mancardi D, Donzelli S, Basudhar D, Ridnour LA, Miranda KM. 2009. The emergence of nitroxyl (HNO) as a pharmacological agent. Biochim Biophys Acta Bioenerg 1787:835-840.
58. Sztrymf B, Yaici A, Girerd B, Humbert M. 2007. Genes and pulmonary arterial hypertension. Respiration 74:123-132.
59. Tamir S, Tannenbaum SR. 1996. The role of nitric oxide (NO·) in the carcinogenic process. Biochim Biophys Acta Rev Cancer 1288:F31-F36.
60. Taylor JGT, Nolan VG, Mendelsohn L, Kato GJ, Gladwin MT, Steinberg MH. 2008. Chronic hyper-hemolysis in sickle cell anemia: Association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One 3:e2095.
61. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. 2000. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 97:2832-2835.
62. Thomas DD, Ridnour LA, Isenberg JS, Flore-Santana W, Switzer C.H, Donzelli S, Hussain P, Vecoli C, Paolocci N, Ambs S, Colton CA, Harris CC, Roberts DD, Wink DA. 2008. The chemical biology of nitric oxide: Implications in cellular signaling. Free Radic Biol Med 45:18-31.
63. Weiner DL, Hibberd PL, Betit P. 2003a. Inhaled nitric oxide therapy for the vaso-occlusive crisis in sickle cell disease. AAP Grand Rounds 9:50-51.
64. Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. 2003b. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 289:1136-1142.
65. Wood KC, Hebbel RP, Granger DN. 2005. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J 19:989-991.
66. Wood KC, Hebbel RP, Lefer DJ, Granger DN. 2006. Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. Free Radic Biol Med 40:1443-1453.
67. Wood KC, Hsu LL, Gladwin MT. 2008. Sickle cell disease vasculopathy: A state of nitric oxide resistance. Free Radic Biol Med 44:1506-1528.
68. Yoon Y, Song J, Hong SH, Kim JQ. 2000. Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clin Chem 46:1626-1630.